AP2655A - Capsule formulation of pirfenidone and pharmaceutically acceptable excipients - Google Patents

Capsule formulation of pirfenidone and pharmaceutically acceptable excipients

Info

Publication number
AP2655A
AP2655A AP2008004390A AP2008004390A AP2655A AP 2655 A AP2655 A AP 2655A AP 2008004390 A AP2008004390 A AP 2008004390A AP 2008004390 A AP2008004390 A AP 2008004390A AP 2655 A AP2655 A AP 2655A
Authority
AP
ARIPO
Prior art keywords
pirfenidone
pharmaceutically acceptable
acceptable excipients
capsule formulation
capsule
Prior art date
Application number
AP2008004390A
Other languages
English (en)
Other versions
AP2008004390A0 (en
Inventor
Ramachandran Radhakrishnan
Ronald Vladyka
Kenneth Sultzbaugh
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37898745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2655(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of AP2008004390A0 publication Critical patent/AP2008004390A0/xx
Application granted granted Critical
Publication of AP2655A publication Critical patent/AP2655A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AP2008004390A 2005-09-22 2006-09-22 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients AP2655A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72025705P 2005-09-22 2005-09-22
PCT/US2006/037057 WO2007038315A2 (en) 2005-09-22 2006-09-22 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients

Publications (2)

Publication Number Publication Date
AP2008004390A0 AP2008004390A0 (en) 2008-04-30
AP2655A true AP2655A (en) 2013-05-07

Family

ID=37898745

Family Applications (2)

Application Number Title Priority Date Filing Date
AP2012006231A AP2012006231A0 (en) 2005-09-22 2006-09-22 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients.
AP2008004390A AP2655A (en) 2005-09-22 2006-09-22 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AP2012006231A AP2012006231A0 (en) 2005-09-22 2006-09-22 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients.

Country Status (28)

Country Link
US (5) US7988994B2 (enExample)
EP (2) EP1940364B2 (enExample)
JP (3) JP5837732B2 (enExample)
KR (3) KR101645069B1 (enExample)
CN (3) CN103393607A (enExample)
AP (2) AP2012006231A0 (enExample)
AU (2) AU2006295440B2 (enExample)
BR (1) BRPI0616324A2 (enExample)
CA (2) CA2762013C (enExample)
CU (1) CU20080043A7 (enExample)
CY (1) CY1115544T1 (enExample)
DK (1) DK1940364T4 (enExample)
EA (1) EA030093B1 (enExample)
EC (1) ECSP088394A (enExample)
ES (1) ES2496144T5 (enExample)
GE (1) GEP20115303B (enExample)
IL (2) IL189273A (enExample)
MA (1) MA29875B1 (enExample)
MX (1) MX2008003882A (enExample)
NO (1) NO345131B1 (enExample)
NZ (3) NZ591443A (enExample)
PL (1) PL1940364T5 (enExample)
PT (1) PT1940364E (enExample)
SI (1) SI1940364T2 (enExample)
TN (1) TNSN08136A1 (enExample)
UA (2) UA115861C2 (enExample)
WO (1) WO2007038315A2 (enExample)
ZA (1) ZA200802237B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE452637T1 (de) 2001-01-29 2010-01-15 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1- phenyl-2-(1h)-pyridon enthält
AU2006244072B2 (en) 2005-05-10 2012-09-20 Intermune, Inc. Pyridone derivatives for modulating stress-activated protein kinase system
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
WO2008077068A1 (en) 2006-12-18 2008-06-26 Intermune, Inc. Method of providing pirfenidone therapy to a patient
US20080242293A1 (en) * 2007-04-02 2008-10-02 Cequint, Inc. System and method for providing caller id name display in wireless communications system
WO2008147169A2 (es) * 2007-05-29 2008-12-04 Cell Therapy Technology, S.A. De C.V. Microemolsion conteniendo pirfenidona
WO2008157786A1 (en) 2007-06-20 2008-12-24 Auspex Pharmaceutical, Inc. Substituted n-aryl pyridinones as fibrotic inhibitors
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
WO2009111785A2 (en) * 2008-03-07 2009-09-11 Solanan, Inc. Treatment of sepsis with 5-ethyl-1-phenyl-2(1h)-pyridone and novel methods for synthesis
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
EP2389227A4 (en) * 2009-01-26 2012-08-08 Intermune Inc METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF
ES2742251T3 (es) 2009-03-16 2020-02-13 Pangu Biopharma Ltd Composiciones y procedimientos que comprenden variantes de splicing de histidil-tarn sintetasa que tienen actividades biológicas no canónicas
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
CN101912395B (zh) * 2010-08-12 2012-09-26 北京凯因科技股份有限公司 一种含吡非尼酮的药物组合物及其制备方法
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
HUE058753T2 (hu) 2011-01-31 2022-09-28 Avalyn Pharma Inc Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik
CA2828895A1 (en) 2011-03-08 2012-09-13 Auspex Pharamaceuticals, Inc. Substituted n-aryl pyridinones
CN102670632A (zh) * 2011-03-12 2012-09-19 赵海静 吡非尼酮在抑制皮肤瘢痕形成的医药用途
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
US20130149383A1 (en) * 2011-12-12 2013-06-13 Cory Berkland Sustained release particle formulations of guaifenesin
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CA2819967C (en) * 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
HK1220133A1 (zh) 2013-03-15 2017-04-28 Intermune, Inc. 改善微血管完整性的方法
CN105378075B (zh) 2013-03-15 2022-04-05 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
KR102349893B1 (ko) 2013-12-13 2022-01-10 노파르티스 아게 제약 투여 형태
AU2015204558B2 (en) 2014-01-10 2020-04-30 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CN110452216B (zh) 2014-04-02 2022-08-26 英特穆恩公司 抗纤维化吡啶酮类
JP6420459B2 (ja) * 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
WO2016059815A1 (ja) * 2014-10-15 2016-04-21 安良太 吾妻 癌化学予防薬
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
KR102051559B1 (ko) * 2016-12-09 2019-12-05 재단법인 아산사회복지재단 섬유증의 진단 또는 치료를 위한 스테아르산의 용도
KR20180100869A (ko) * 2017-03-02 2018-09-12 영진약품 주식회사 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법
US11767520B2 (en) 2017-04-20 2023-09-26 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
PT3511001T (pt) * 2018-01-12 2021-12-29 Tiefenbacher Alfred E Gmbh & Co Kg Formulação de comprimido e cápsula contendo pirfenidona
CN112469406B (zh) * 2018-05-31 2024-05-17 财团法人峨山社会福祉财团 硬脂酸用于预防或治疗肺纤维化的用途
US20210267955A1 (en) * 2018-06-29 2021-09-02 Zenvision Pharma Llp Low dose oral pharmaceutical composition of pirfenidone or salt thereof
WO2020115774A1 (en) 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
WO2021157681A1 (ja) * 2020-02-06 2021-08-12 株式会社リボミック 網膜下高反射病巣または網膜下高反射病巣を伴う網膜疾患の治療剤
US20230129866A1 (en) * 2020-03-13 2023-04-27 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone
WO2021198253A1 (en) 2020-04-01 2021-10-07 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions
CA3175526A1 (en) * 2020-04-14 2021-10-21 Estuardo Aguilar-Cordova Pirfenidone for coronavirus treatment
WO2021215856A1 (ko) * 2020-04-22 2021-10-28 영진약품 주식회사 안전성과 안정성이 개선된 피르페니돈을 포함하는 장용성 제제 및 이의 제조방법
US20240238368A1 (en) 2021-01-25 2024-07-18 Nibec Co., Ltd. Peptide for preventing and treating fibrosis
CN117224429B (zh) * 2023-11-15 2024-02-06 南京天纵易康生物科技股份有限公司 一种含羟乙基纤维素作为崩解剂的烟酰胺/肽类固液分离护肤组合物及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
JPH02215719A (ja) † 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5518729A (en) * 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
AU687816B2 (en) * 1993-05-07 1998-03-05 Solomon B. Margolin Compositions and methods for reparation and prevention of fibrotic lesions
US5591766A (en) * 1993-12-03 1997-01-07 Cheil Foods & Chemicals, Inc. Solid oral formulations of pyridone carboxylic acids
US6090822A (en) * 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
US5962478A (en) * 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
AU709178B2 (en) * 1995-09-19 1999-08-26 Intermune, Inc. Inhibition of tumor necrosis factor alpha
EP1269995A1 (en) * 2000-03-27 2003-01-02 Kyowa Hakko Kogyo Co., Ltd. Easy-to-take granule
ATE452637T1 (de) 2001-01-29 2010-01-15 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1- phenyl-2-(1h)-pyridon enthält
WO2002087549A1 (fr) * 2001-04-25 2002-11-07 Taisho Pharmaceutical Co., Ltd. Comprimes a liberation prolongee du type a unites multiples
US7007089B2 (en) * 2001-06-06 2006-02-28 Akarnai Technologies, Inc. Content delivery network map generation using passive measurement data
US7512702B1 (en) * 2002-03-19 2009-03-31 Cisco Technology, Inc. Method and apparatus providing highly scalable server load balancing
US7139840B1 (en) * 2002-06-14 2006-11-21 Cisco Technology, Inc. Methods and apparatus for providing multiple server address translation
WO2004019758A2 (en) 2002-08-27 2004-03-11 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
WO2004019863A2 (en) 2002-08-28 2004-03-11 Intermune, Inc. Combination therapy for treatment of fibrotic disorders
US7159034B1 (en) * 2003-03-03 2007-01-02 Novell, Inc. System broadcasting ARP request from a server using a different IP address to balance incoming traffic load from clients via different network interface cards
RS20050714A (sr) * 2003-03-31 2008-04-04 Pliva-Lachema A.S., Farmaceutski preparati koji kao aktivnu suptancu sadrže kompleks platine i postupci za njihovo dobijanje
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
US20070092488A1 (en) 2003-05-16 2007-04-26 Intermune Inc. Methods of treating idiopathic pulmonary fibrosis
CA2525647A1 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
MXPA06000178A (es) * 2003-07-01 2006-04-11 Pharmacia & Upjohn Co Llc Solidos modulados en la fase de difusion.
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
CA2545813C (en) 2003-11-14 2011-01-04 Shanghai Genomics, Inc. The derivatives of pyridone and use thereof
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US7584435B2 (en) * 2004-03-03 2009-09-01 Omniture, Inc. Web usage overlays for third-party web plug-in content
EP2305697A3 (en) * 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients

Also Published As

Publication number Publication date
AU2006295440A1 (en) 2007-04-05
CN103393607A (zh) 2013-11-20
CY1115544T1 (el) 2017-01-04
US20090191265A1 (en) 2009-07-30
EA030093B1 (ru) 2018-06-29
AP2012006231A0 (en) 2012-04-30
BRPI0616324A2 (pt) 2011-06-14
US20120015984A1 (en) 2012-01-19
KR101645069B1 (ko) 2016-08-02
IL189273A0 (en) 2008-06-05
DK1940364T4 (da) 2022-10-24
US8383150B2 (en) 2013-02-26
CU20080043A7 (es) 2011-04-26
UA99433C2 (ru) 2012-08-27
IL239868A0 (en) 2015-08-31
IL189273A (en) 2016-09-29
ES2496144T5 (es) 2022-11-21
SI1940364T2 (sl) 2022-11-30
CA2620380C (en) 2012-10-30
AP2008004390A0 (en) 2008-04-30
JP2014169341A (ja) 2014-09-18
AU2006295440B2 (en) 2011-01-06
AU2011201520B2 (en) 2013-04-11
WO2007038315A2 (en) 2007-04-05
CA2762013C (en) 2014-07-08
EP1940364B1 (en) 2014-06-11
US20100152250A1 (en) 2010-06-17
CA2762013A1 (en) 2007-04-05
GEP20115303B (en) 2011-10-10
MA29875B1 (fr) 2008-10-03
PT1940364E (pt) 2014-09-04
HK1117762A1 (en) 2009-01-23
KR20140029554A (ko) 2014-03-10
JP2009509962A (ja) 2009-03-12
NO345131B1 (no) 2020-10-12
TNSN08136A1 (en) 2009-07-14
PL1940364T5 (pl) 2023-02-27
EP1940364A2 (en) 2008-07-09
CN101267810A (zh) 2008-09-17
KR101675651B1 (ko) 2016-11-11
CN103735530A (zh) 2014-04-23
ECSP088394A (es) 2008-05-30
CA2620380A1 (en) 2007-04-05
EP1940364B2 (en) 2022-07-20
AU2011201520A1 (en) 2011-04-28
KR20080046673A (ko) 2008-05-27
ZA200802237B (en) 2010-04-28
PL1940364T3 (pl) 2014-11-28
ES2496144T3 (es) 2014-09-18
JP5837732B2 (ja) 2015-12-24
NZ600129A (en) 2013-12-20
US8753679B2 (en) 2014-06-17
MX2008003882A (es) 2009-02-27
EP2431025A1 (en) 2012-03-21
US7988994B2 (en) 2011-08-02
US20140242159A1 (en) 2014-08-28
SI1940364T1 (sl) 2014-09-30
DK1940364T3 (da) 2014-06-30
NZ591443A (en) 2013-04-26
UA115861C2 (uk) 2018-01-10
JP5715101B2 (ja) 2015-05-07
EA200800881A1 (ru) 2008-08-29
WO2007038315A3 (en) 2007-07-12
KR20130100381A (ko) 2013-09-10
JP2012224641A (ja) 2012-11-15
NZ565957A (en) 2012-04-27
US20130165484A1 (en) 2013-06-27
US7767225B2 (en) 2010-08-03
NO20080759L (no) 2008-06-18

Similar Documents

Publication Publication Date Title
AP2655A (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
IL184735A0 (en) Pharmaceutical formulations and methods of use
AP2008004447A0 (en) Orally absorbed pharmaceutical formulation and method of administration
TWI367212B (en) Dosage forms of palonosetron hydrochloride having improved stability and bioavailability
ZA200901110B (en) Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage from containing same
IL196854A (en) Indole compounds and their appropriate pharmaceutical salts and their use in the preparation of @ drugs
IL188744A0 (en) High drug load formulations and dosage forms
IL202111A0 (en) Formulations for the oral administration of therapeutic agents and related methods
IL184697A0 (en) Injectable preparations of diclofenic and its pharmaceutically acceptable salts
IL178067A0 (en) Pharmaceutical dosage forms and compositions
PL1655026T3 (pl) Zawierające diacereinę i meloksikam stałe preparaty farmaceutyczne
EP1968609A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE USE OF HIGHLY LIPOPHILIC SULFHYDRYL COMPOUNDS
PL385455A1 (pl) Doustna rozpadająca się farmaceutyczna tabletka preparatów olanzapiny
IL191922A0 (en) Pharmaceutical formulations of oxcarbazepine and methods for its preparation
EP1855647A4 (en) DELAYED RELEASE PHARMACEUTICAL ORAL DOSAGE FORM AND METHOD OF MANUFACTURING THE SAME
EP1740541A4 (en) THERAPEUTIC FORMULATIONS OF DESOXYEPOTHILONES
GB0711654D0 (en) Formulations for production of capsule shells and capsules
WO2007119249A3 (en) Pharmaceutical compositions of cefixime
GB0610207D0 (en) New forms of active pharmaceutical ingredient
PL380757A1 (pl) Nowe pochodne epirubicyny, ich nowe zastosowanie medyczne oraz farmaceutycznie akceptowalna postać leku
HK1123205A (en) Orally absorbed pharmaceutical formulation and method of administration